MTOR and desmoplastic small round cell tumor: The mTOR-inhibitor ridafirolimus achieved a 4-month stable response in a patient with DSRCT previously treated with chemotherapy and sunitinb with an overall survival of 38 months (35) and another heavily pretreated patient with DSRCT who was given temsirolimus achieved prolonged stabilization before progression (50).